Astera Labs enters the second half of May with short sellers in full retreat and a wall of analyst upgrades pushing the stock to $244 — a 19% gain on the week and 40% higher than a month ago.
Short sellers have been quietly unwinding a crowded position. SI % FF has fallen from a peak near 10.9% in mid-April to 8.1% now — a drop of roughly 2.8 percentage points as the stock rallied hard post-earnings. That unwind accelerated this week, with short shares declining a further 3.8%. The move looks like forced covering rather than conviction: the borrow market tells a very different story. Cost to borrow has climbed 55% over the week to just under 0.5%, suggesting demand for new borrows is rising even as shorts exit. Availability remains extremely loose at 1,916% — nearly nineteen times as many shares available as currently shorted — so the borrow squeeze narrative doesn't apply here. What's happening is shorts are getting squeezed by price, not by supply.
The options market is not adding much fear. The put/call ratio has drifted slightly below its 20-day average to 0.82, roughly 0.8 standard deviations on the call-heavy side of normal. After climbing above 0.9 during the more uncertain period in late April and early May, the ratio has been easing as the stock rallied. The 52-week range for the PCR runs from 0.62 to 1.03, so the current reading is comfortably mid-range — not euphoric, but clearly less hedged than a fortnight ago.
Analyst reaction to the Q1 beat has been broad and emphatic. Nearly every firm covering ALAB raised its target after the May 6 print, with the direction universally higher. Evercore ISI moved fastest, boosting its target to $297 from $215 just yesterday and maintaining Outperform. JPMorgan went to $280 from $205 with an Overweight rating. The mean target across the Street now stands at $244 — essentially where the stock is trading — which means the post-earnings rally has already consumed most of the formal upside. The outliers are Evercore at $297 and RBC at $270 on the bull side; Barclays sits at $200 with an Equal-Weight, and TD Cowen holds at $225 on a Hold, suggesting not everyone is convinced the premium is sustainable. The bull case centres on AI infrastructure demand, hyperscaler relationships, the aiXscale acquisition, and an optical portfolio ramp targeting FY27. The bear case is blunter: AVGO, MRVL, and CRDO are all credible competitors, and the customer base is dangerously concentrated among a handful of hyperscalers. Valuation multiples reflect that debate — PE is now running at 70.6x, up more than 8 points over the past month, and EV/EBITDA has expanded nearly 7 points in a week to just under 60x.
Insider activity adds a note of caution. On May 7, co-founder and President Sanjay Gajendra sold approximately $24 million worth of shares across multiple tranches at prices between $193 and $206. CEO Jitendra Mohan sold a further $1.2 million the same day. The timing — immediately after the earnings beat — looks like planned monetisation rather than a directional signal, and the net 90-day position across all insiders is actually slightly positive in share count terms. But the scale of the founder selling, at prices well below where the stock closed this week, underscores how quickly sentiment has shifted. Institutional holders including FMR, Vanguard, and BlackRock all modestly added to positions in Q1, providing structural ballast.
The ORTEX short score has been drifting lower all week, from 46.8 on May 6 to 44.1 today. That reflects the combination of unwinding SI and loosening borrow conditions — the short-side setup is becoming less charged, not more. Factor scores show strong EPS momentum (86th percentile on the 30-day measure, 75th on 90-day), and the analyst recommendation differential ranks at the 88th percentile — the Street is skewing notably bullish relative to the broader universe. With the stock now trading right at the mean analyst target and the next earnings event not yet scheduled, the key tension to watch is whether the gap between the Street bulls above $270 and the cautious holds around $200–225 starts to close, or whether the premium multiples begin to attract renewed short interest as the post-earnings momentum fades.
See the live data behind this article on ORTEX.
Open ALAB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
